Lipocine (LPCN) Accumulated Expenses (2012 - 2025)
Lipocine's (LPCN) quarterly Accumulated Expenses came in at $1.2 million in Q4 2025, up 34.21% YoY from $921240.0 in Q4 2024, and up 64.92% on a QoQ basis from $749667.0 in Q3 2025.
Lipocine (LPCN) Accumulated Expenses (2012 - 2025) Analysis & Trends
Lipocine (LPCN) has 14 years of Accumulated Expenses data on file, last reported at $1.2 million in Q4 2025.
- Quarterly Accumulated Expenses rose 34.21% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (up 34.21% YoY) and the FY2025 annual result came in at $1.2 million, up 34.21% from the prior year.
- Accumulated Expenses improved to $1.2 million in Q4 2025, from $749667.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $2.5 million in Q2 2021 to a low of $619410.0 in Q1 2025.
- A 5-year average of $1.1 million and a median of $1.1 million in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2021 — Accumulated Expenses surged 151.7% — and 2022, when it sank 64.03%.
- Tracing LPCN's Accumulated Expenses over 5 years: stood at $1.0 million in 2021, then grew by 6.03% to $1.1 million in 2022, then climbed by 13.06% to $1.2 million in 2023, then dropped by 24.39% to $921240.0 in 2024, then surged by 34.21% to $1.2 million in 2025.
- The last three Accumulated Expenses figures came in at $1.2 million (Q4 2025), $749667.0 (Q3 2025), and $685779.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.24 Mn |
| Sep 30, 2025 | 749,667.00 |
| Jun 30, 2025 | 685,779.00 |
| Mar 31, 2025 | 619,410.00 |
| Dec 31, 2024 | 921,240.00 |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 761,465.00 |
| Dec 31, 2023 | 1.22 Mn |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 1.31 Mn |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 880,850.00 |
| Jun 30, 2022 | 899,301.00 |
| Mar 31, 2022 | 1.00 Mn |
| Dec 31, 2021 | 1.02 Mn |
| Sep 30, 2021 | 1.57 Mn |
| Jun 30, 2021 | 2.50 Mn |
| Mar 31, 2021 | 1.50 Mn |